TY - JOUR
T1 - Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
AU - Doulaptsi, Maria
AU - Wils, Tine
AU - Hellings, Peter W.
AU - Martens, Katleen
AU - Farré, Ricard
AU - Vicario, Maria
AU - Fokkens, Wytske
AU - Prokopakis, Emmanuel
AU - Steelant, Brecht
N1 - Funding Information: This work was supported by an unrestricted grant from GSK . BS is supported by the Fund for Scientific Research Flanders ( FWO ), Belgium. Publisher Copyright: © 2021
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Tight junction defects (TJ) have been associated with a defective epithelial barrier function in allergic rhinitis (AR). Intranasal corticosteroids are potent drugs frequently used to treat AR and are shown to restore epithelial integrity by acting on TJs and by reducing type 2 cytokine production. However, the effect of different classes of intranasal corticosteroids on the epithelial barrier has not been studied. Therefore, we compared the effect of 2 intranasal corticosteroids, ie, fluticasone furoate (FF) and mometasone furoate (MF) on epithelial barrier function. Both FF and MF similarly increased trans-epithelial electrical resistance of primary nasal epithelial cell cultures from AR patients. In a house dust mite-induced allergic asthma mouse model, FF and MF had similar beneficial effects on fluorescein isothiocyanate–dextran 4 kDa mucosal permeability, eosinophilic infiltration and IL-13 levels. Both molecules increased mRNA expression of the TJ proteins occludin and zonula occludens-1, thereby restoring epithelial barrier function. Lastly, we showed that long-term FF treatment also increased expression of occludin in AR patients compared to controls. In conclusion, both FF and MF effectively restore epithelial barrier function by increasing expression of TJ proteins in AR patients.
AB - Tight junction defects (TJ) have been associated with a defective epithelial barrier function in allergic rhinitis (AR). Intranasal corticosteroids are potent drugs frequently used to treat AR and are shown to restore epithelial integrity by acting on TJs and by reducing type 2 cytokine production. However, the effect of different classes of intranasal corticosteroids on the epithelial barrier has not been studied. Therefore, we compared the effect of 2 intranasal corticosteroids, ie, fluticasone furoate (FF) and mometasone furoate (MF) on epithelial barrier function. Both FF and MF similarly increased trans-epithelial electrical resistance of primary nasal epithelial cell cultures from AR patients. In a house dust mite-induced allergic asthma mouse model, FF and MF had similar beneficial effects on fluorescein isothiocyanate–dextran 4 kDa mucosal permeability, eosinophilic infiltration and IL-13 levels. Both molecules increased mRNA expression of the TJ proteins occludin and zonula occludens-1, thereby restoring epithelial barrier function. Lastly, we showed that long-term FF treatment also increased expression of occludin in AR patients compared to controls. In conclusion, both FF and MF effectively restore epithelial barrier function by increasing expression of TJ proteins in AR patients.
KW - Allergic rhinitis
KW - Epithelial integrity
KW - Fluticasone furoate
KW - Mometasone furoate
KW - Tight junctions
UR - http://www.scopus.com/inward/record.url?scp=85114747408&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.waojou.2021.100585
DO - https://doi.org/10.1016/j.waojou.2021.100585
M3 - Comment/Letter to the editor
C2 - 34567350
SN - 1939-4551
VL - 14
JO - World Allergy Organization Journal
JF - World Allergy Organization Journal
IS - 9
M1 - 100585
ER -